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Summary Immunoreactive inhibin-like material (ILM) was measured by radioimmunoassay (RIA) in serum
and gastric juice samples of 23 fasting normal men, 27 men with chronic superficial gastritis (CSG), and 21
men with carcinoma of stomach (5 for gastric analysis). Serum ILM levels in carcinoma of stomach patients
(367+55.5ngml-1) were significantly higher than in normal men (15.4+2.6ngml-1; P<0.01) and in patients
with CSG (109.8 +17.7 ngml- 1; P<0.05). Sixty two per cent and 86% ofpatients with carcinoma of stomach
showed elevated ILM levels which were higher than the highest noted in patients with CSG and normal men
respectively.
For many years past, a number of investigations
have been carried out to compare normal and
malignant conditions with a view to find out
quantitative or qualitative changes in the various
parameters studied. We have earlier reported
studies on human chorionic gonadotropin and
human placental lactogen in gastric juice and serum
of patients with cancer of the. stomach and allied
pathological conditions (Shinde et al., 1981; Sheth
et al., 1980). Here we present our findings on
inhibin, a peptide which is involved in suppression
of follicle-stimulating hormone (FSH) from
pituitary, the isolation and amino acid structure of
which has been reported (Sheth et al., 1984a;
Seidah et al., 1984; Johansson et al., 1984). We
have previously demonstrated the presence of bio-
immunoactive inhibin-like peptide in gastric juice of
normal men (Sheth et al., 1982) and also the status
of ILM in gastric juice and serum of patients with
duodenal ulcer (Shanbhag et al., 1984).
We have carried out preliminary studies on
inhibin-like peptide in serum samples of 9 patients
with carcinoma of stomach (Sheth et al., 1984b). In
the present study using RIA, we report the levels of
inhibin-like material (ILM) in the serum samples of
patients with carcinoma of stomach and in gastric
juice and serum of fasting normal men and patients
with chronic superficial gastritis (CSG).
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Materials and methods
Serum samples from 21 fasting men with carcinoma
of the stomach were obtained from Tata Memorial
Hospital, Bombay. It was possible to collect gastric
juice from only 5 of the above patients. The control
group included 23 fasting normal healthy men and
27 men with benign pathological conditions.
Gastric juice and serum samples from the above
patients were obtained from Lokmanya Tilak
Municipal Hospital, Bombay. Sixteen of the 27
patients had CSG, 2 had mild gastritis and 9 had
other gastrointestinal lesions viz. duodenal ulcer
(DU) or duodenitis in addition to CSG.
The age of normal men and patients with
carcinoma of stomach or CSG varied from 30-50
years. Men admitted to the hospital were kept
fasting for a period of 12h from 22.00h to 10.00h.
Diagnosis was based on histological sections of
multiple (at least two) gastric biopsies and brush
cytology taken under vision with a fibreoptic
gastroscope. Cancer patients were at stage III or IV
at the time of diagnosis according to TNM
classification. Samples of gastric juice and blood
were collected in the morning and kept at 4°C
throughout the experimental procedure.
Immediately after collection, each sample of gastric
juice was centrifuged at 800g at 4°C for 10min.
The pH of the supernatant was recorded and
adjusted to 7.0 with 1 M NaOH. The supernatants
and sera were stored at -20°C for subsequent
analysis. No enzyme inhibitor was added to the
gastric juice samples as we have previously shown
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that there is no breakdown of ILM in the system
used.
Antigen
ILM levels were measured by homologous RIA as
described earlier (Shanbhag et al., 1984). A
homologous preparation of ILM isolated from
human seminal plasma as described by Thakur et
al. (1981) was used as a reference standard and as
antigen for radioiodination by 125I. The relative
specificity and sensitivity of available bioassays for
determination of inhibin-like activity have been
discussed (Moodbirdi et al., 1980). The long term
castrate adult rat model-although not very sensitive
is very specific, whereas the specificity of the hCG
primed rat ovarian weight method although rapid
for monitoring inhibin activity, is not well defined.
The biological activity of antigen used in the
present study was measured by various in vitro as
well as in vivo assays and found to be biologically
active. The antigen administered to castrated male
rats caused 50-60% inhibition of FSH levels and
had no effect on the LH levels indicating a specific
effect on FSH release (Vijayalakshmi et al., 1981).
The above criteria meet the general requirement for
inhibin-like activity. When analysed by poly-
acrylamide gel electrophoresis, this biologically
active peptide moved as a single band protein at
500pg concentration suggesting homogeneity of the
material. Its properties on reverse phase high
pressure liquid chromatography established that the
preparation is a single homogeneous peptide (Sheth
et al., 1984a) with a molecular weight of 14,000
daltons.
Antiserum
Antibodies to ILM were raised in a rabbit by active
immunization. In vivo and in vitro neutralisation
experiments were carried out as described earlier by
Sheth et al. (1984b) to eftsure that the antibodies
formed were against the biologically active sites of
ILM. The antiserum was capable of binding 50%
of radioiodinated ILM at a dilution of 1:10,000.
From a Scatchard analysis, the affinity constant for
the ILM antiserum was calculated as
2.06x 1010moll-'. Different dilutions of serum
when analysed by the present RIA gave a dose
response line parallel to that of the standard ILM.
The slope calculated from these lines was
comparable to that of standard purified ILM. Anti-
rabbit gamma globulin (ARGG) was raised in
sheep in our laboratory.
Radioimmunoassay
RIA developed at this laboratory using the antigen
and antiserum described above was used for the
present study. Carrier-free 1251I (Sp. act. 11-
17mCigg-1) was obtained from Radiochemical
Centre, Amersham, Bucks, UK. lodination was
carried out according to the method of Greenwood
et al. (1963) with appropriate modification (Sheth
et al., 1984b). The specific activity of the labelled
hormone ranged from 100 to l50pCipg-1 ILM.
Homologous RIA was carried out by the double
antibody technique.
The sensitivity of the assay was 0.5-30ng of ILM
per assay tube. Ten ng of ILM gave 50% inhibition
of specific binding in the assay system. The intra-
and inter-assay coefficients of variation were 5-7%
and 10-15% respectively. Specificity of the assay
was checked against peptides of gastrointestinal,
pituitary, placental and foetal origin (Table I). The
specificity of the assay system against serum factors
other than gonadal inhibin was checked by
examining sera from ovariectomized women in
which concentrations of ILM were found to be
significantly low. Concentrations of serum ILM in
ovariectomized women ranged from 2-4ngml-
which were significantly lower than in normal
women (30-100ngml-1). Serum and gastric juice
samples from all the groups were analysed in a
single assay to avoid inter-assay variation. The
assay was performed at 0-40C and was repeated
twice to confirm the analysis. Statistical significance
of the data was carried out using analysis of
variance (Snedecor & Cochran, 1967).
Results
Figure 1 shows serum IR-ILM concentrations in
normal, healthy subjects and in patients with
malignant and non-malignant diseases of the
stomach. From analysis of variance F (2,59) was
found to be 31.65 which is highly significant
(P<0.001) showing that the three groups viz
normal (15.4+2.6ngml 1), CSG (109.8
+ 17.7ngml-1) and carcinoma of stomach (367
+55.5ngml-1) differ significantly. Using Keul's
method for locating the significant differences, it
was found that the difference between carcinoma of
stomach and normal was significant at the level of
1%. Similarly, CSG was different from carcinoma
of stomach and normal at the level of 5%.
Figure 2 shows IR-ILM concentration in the
gastric juice of various groups. As indicated in the
scattered diagram, the mean (±s.e.) ILM concen-
tration of 132.4± 59.3ngml-1 in CSG patients,
262.5+ 129.1 ngml1 in CSG+other gastrointestinal
lesion patients and 20.5+6.3ngml-1 in
carcinoma of stomach patients was not significantly
different from that in normal (52.14±11.6ngml-1).
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Table I Gastrointestinal Tract Peptides and other peptides and Protein Hormones checked for cross reactivity in
RIA of ILM
Concentration at which
cross reactivity was checked
andfound to give no
Hormone/Peptide Source reactiona
(1) Gastrin, (2) Neurotensin,
(3) Gastric inhibitory peptide,
(4) Oxytocin, (5) Secretin, (6) Substance P,
(7) Vasoactive intestinal polypeptide, Human 10ng, 100ng and 1 pg
(8) Leu-enkephalin, (9) Motilin, J
(10) Soma-tostatin, (11) Pancreatic polypeptide,
(12) Pancreozymin, (13) Bombesin
(14) Relaxin Human 1jig and 2pg
(15) Alpha-fetoprotein Human 1 pg and 2pg
(16) Follicle stimulating
hormone, (17) Luteinizing hormone, Human 1 pg and 2pg (18) Prolactin, (19) Chorionic }
gonadotrophin, (20) Placental lactogen
(21) Carinoembryonic antigen Human lOng and 0.5upg
(22) Epidermal growth factor Mouse salivary gland 1pg and 2pg
(23) Enhancing factor Mouse small intestine 45pg
(partially purified)
al0ngILM gave 50% inhibition of the specific binding in the RIA. The peptides listed above did not show any
competition for binding to the antiserum at the dilutions tested. 1-13: gift from Serono, Italy; 14: gift from Dr D.
Sherwood, USA; 15: gift from WHO; 16-20: gift from NIAMMD, Bethesda, USA; 21: gift from Abbot Labs, USA;
22: gift from Collaborative Research Inc; 23: gift from Dr R. Mulherkar (Deo et al., 1983).
n=25 n=16 n = 3
I 0.0
n = 9
T * * -a
Mild CSG + other
gastritis Gl lesion
Figure 1 ILM levels expressed ml
' of serum in fasting normal men and patients with chronic superficial
gastritis (CSG), mild gastritis, CSG + other gastrointestinal lesion and carcinoma of stomach. 'Normal vs






















































Figure 2 ILM levels expressed ml-l of gastric juice in fasting normal men and patients with chronic
superficial gastritis (CSG), mild gastritis, CSG+other gastrointestinal lesion and carcinoma ofstomach.
other gastrointestinal lesion patients had ILM con-
centrations > 179ngml', the highest value noted
in normals.
Table I gives the list of gastrointestinal tract
peptides and other peptides and protein hormones
which were checked for cross reactivity in the assay
system. Ten ng of ILM showed 50% inhbition of
specific binding to antiserum whereas it was
interesting to note that none of the above
mentioned peptides were capable of competing for
binding to the antiserum at various dilutions tested.
The pH of the gastric juice in CSG patients and
normal men was noted; it ranged from 2.4-7.6 and
1.4-5.2 respectively. A significant correlation was
not found between pH and ILM concentrations in
the gastric juice of patients with CSG. This
observation is similar to the one noted earlier in
DU patients but is in contrast to that in normal
men. As reported earlier (Shanbhag et al., 1984) the
concentration of ILM before and after the
neutralization of gastric juice was found to be
similar, suggesting that variation in gastric juice pH
does not interfere in the RIA.
Discussion
One of the notable findings from the present study
was that the mean ILM concentration in the sera of
patients with CSG was 7 times higher than that in
normal men. Evidence accumulated during the past
few decades suggests a relationship between gastric
carcinoma and chronic gastritis (Sipponen et al.,
1984; Siurala & Salmi, 1971; Ihamaki et al., 1978)
but somewhat conflicting results have also been
reported (Elsborg & Mosbech, 1979). In the light of
the above findings, it was interesting that serum
ILM levels in patients with carcinoma of the
stomach were still further elevated with a mean of
367+55.5ngml-P, which was 3 times higher than
that in patients with CSG. As reported by
Bagshawe (1983) it is correct that a statistically
significant difference existing between cancer and
non-cancer groups is of limited value when
translated to individual patients. For this reason,
the increased levels of ILM in carcinoma of
stomach appear to be of significance as 62% of
these patients when considered individually had
I
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higher ILM concentrations than the highest value
of 269ngml-1 found in CSG. When compared to
normal, the mean serum ILM concentration in these
patients was found to be 20 fold higher with 86%
of patients showing levels which were >43 ngml-1,
the highest level observed in normal subjects. It is
worthwhile to compare serum ILM levels of
carcinoma of stomach with that in another benign
condition studied earlier, viz. DU (Shanbhag et al.,
(1984). Mean serum ILM concentration in DU
patients though higher than normal was found to
be much lower than carcinoma of the stomach and
even that of GSC. It may be noted that an increase
of serum ILM concentration, in comparison with
normal healthy subjects, is not confined to benign
and malignant diseases of the gastrointestinal tract.
We have earlier reported elevated levels of ILM in
sera of patients with malignant and non-malignant
diseases of prostrate and stomach in men and lung
and breast in women (Sheth et al., 1984a). But the
rise in ILM concentration in the sera of patients
with carcinoma of the stomach was found to be
highest among all the other benign or malignant
diseases studied. Our preliminary study on serum
ILM concentration of 8 leukaemic patients did not
show any difference from normal. Since ILM is
detected in gastric mucosa and gastric juice, it
remains to be ascertained whether the elevated
serum ILM is from a gonadal and/or gastro-
intestinal source. ILM levels in the gastric juice of
the groups studied were comparable with normal.
In conclusion, it is apparent that serum ILM
concentration is elevated in the majority of gastric
cancer patients. Further investigations are necessary
to evaluate whether serum ILM is a promising
index for detecting patients at risk for gastric
cancer.
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